Reprogramming of somatic cells to a state of pluripotency is characterized by prolonged self-renewal, implying induction of telomere maintenance mechanisms. Recently, it was reported that reprogramming of mouse cells was accompanied by elongation of telomeres
8, but given the significant differences in telomere length and telomerase regulation in mouse and human cells, we asked whether normal human cells displayed telomere elongation after reprogramming. We generated iPS cell lines by retroviral transduction of primary human fibroblasts with the factors
Oct4,
Sox2,
Klf4, and
c-Myc, confirmed the pluripotent phenotype by gene expression and functional analysis
4, and determined the mean terminal restriction fragment (TRF) length of the donor fibroblast lines and corresponding iPS lines by Southern blot. We found that mean TRF length and total telomeric DNA was increased in iPS lines relative to the parental fibroblasts (
Supplementary Fig. 1a). Similar findings using retrovirally-marked single-cell fibroblast sub-clones
5 argued against the notion that cells with long telomeres are uniquely susceptible to reprogramming (
Supplementary Fig. 1b). Induction of
TERT expression and telomerase activity correlated with reprogramming to pluripotency as previously shown
5–7 (
Supplementary Figs. 1c–e). These data establish that direct factor-based reprogramming of human somatic cells results in net telomere elongation.
X-linked DC is caused by mutations in the dyskerin gene (
DKC1)9 which encodes an RNA binding protein whose inactivation destabilizes levels of
TERC, resulting in shortened telomeres and premature senescence in patient cell lines
10,11. We asked whether a
DKC1 mutant fibroblast line (del37L
9–11) could be reprogrammed and propagated in a pluripotent state. Compared to normal cells, the reprogramming efficiency of del37L cells was poor, yielding only 2–5 colonies from 10
5 input cells with a delayed latency (
Supplementary Table 1). Nevertheless,
DKC1 mutant iPS colonies showed all hallmarks of pluripotency, including characteristic morphology (), gene expression (;
Supplementary Fig. 2a), and formation of teratomas comprised of all three embryonic germ layers (). PCR restriction fragment length polymorphism (RFLP) analysis for the
DKC1 mutation confirmed the del37L mutation in iPS lines, and karyotype analysis was normal (;
Supplementary Fig. 2b,c). These data show that the somatic cells from patients with a genetic impairment in telomere elongation can be reprogrammed to pluripotency.
Despite induction of endogenous
TERT and telomerase activity (,e), early passage del37L iPS cell lines displayed shorter telomeres relative to the starting fibroblast population (). Addition of
TERT to the reprogramming factors did not result in telomere elongation in del37L mutant cells (), unlike in normal cells (
Supplementary Fig. 3), but did increase reprogramming efficiency (
Supplementary Table 1;
Supplementary Text). We obtained similar results with reprogramming of an independent
DKC1 mutant line (A386T
11) (;
Supplementary Fig. 4;
Supplementary Table 1). Given the telomerase dysfunction and shortened telomeres, we expected to observe limited passage of
DKC1 mutant iPS cells in culture. However, unlike the parental
DKC1 mutant fibroblasts, which senesced after 3–4 passages, we were able to continuously culture the
DKC1 mutant iPS cell lines. Compared to the early passage cells, we found by TRF analysis that telomere length in del37L iPS lines increased with continued passage (). Consistent with this, despite numerous interval population doublings, late passage del37L iPS lines had telomere lengths comparable to the original fibroblast population by quantitative PCR
12 (). In a blinded assessment by the complementary method of quantitative telomere fluorescence
in situ hybridization, we confirmed that telomere length was shortened immediately after derivation but increased over time (). Late passage del37L iPS cells maintained a characteristic morphology, normal karyotype, and the same clonal fingerprint as early passage cells, and reversion of the genetic mutation in
DKC1 was excluded (
Supplementary Fig. 5). These data show that even in cells carrying genetic lesions that reduce telomerase function, reprogramming restores telomere elongation and self-renewal.
Previous studies have shown that reduced
TERC levels compromise telomerase activity in
DKC1 mutant fibroblasts
11. Ectopic expression of
TERT alone results in telomere elongation in wild-type fibroblasts
13,14, whereas expression of both
TERC and
TERT is required to restore telomere elongation in
DKC1 mutant fibroblasts
11 (
Supplementary Fig. 6). We therefore investigated
TERC levels in DC fibroblasts and iPS cells. By quantitative RT-PCR, we found that
TERC levels in
DKC1 mutant fibroblasts were 10–15% of
TERC levels found in wild-type fibroblasts, consistent with previous reports
10,11 (). Relative to parental fibroblasts from two patients with different
DKC1 mutations, we found
TERC levels increased 6–8 fold in the reprogrammed derivatives, approaching levels in normal fibroblasts (). In normal iPS cells, we found that
TERC levels were approximately 3-fold higher than the fibroblasts from which they were derived (). We next examined a cell line from a patient with autosomal dominant DC carrying a heterozygous 821 bp deletion in the 3' region of the
TERC locus (DCHSF1
15,16). In these
TERC+/− fibroblasts
TERC is limiting for telomere elongation, even in the presence of exogenous
TERT16. We reprogrammed the
TERC+/− patient fibroblasts and obtained multiple independent iPS lines which all showed characteristics of pluripotency and maintained the mutant genotype (
Supplementary Fig. 7).
TERC+/− iPS cells also showed a 3-fold induction of
TERC relative to fibroblasts (), and displayed continuous self-renewal in contrast to the early senescence seen in the parental fibroblasts
16. These data demonstrate that reprogramming of somatic cells is accompanied by upregulation of endogenous
TERC levels, and provide a mechanism for telomere elongation and indefinite self-renewal in DC iPS cell lines (
Supplementary Fig. 6).
We found that human embryonic stem (ES) cells maintain elevated
TERC levels similar to those found in WT iPS cells (), and that
TERC levels attained in iPS cell lines derived from
DKC1 mutant,
TERC+/− and WT cells correlated with their respective telomerase activity (). Furthermore,
TERC knockdown in DC iPS lines compromised telomere maintenance (
Supplementary Fig. 8a). We found that the
TERC locus is not amplified in DC iPS cells, and that upon differentiation of DC iPS cells,
TERC expression reverted to the pathologically low levels found in patient fibroblasts, and telomere length decreased (
Supplementary Figs. 8b–d). Collectively, these results show that
TERC levels are increased by reprogramming, and are a dynamically regulated and reversible property of the pluripotent state.
TERC abundance is tightly regulated by multiple transcriptional and post-transcriptional mechanisms
17,18. To investigate transcriptional mechanisms of
TERC upregulation, we performed chromatin immunoprecipitation (ChIP) in human iPS cells, and detected enhanced binding of Oct4 and Nanog in the
TERC locus (). These data were corroborated in murine ES cells, which likewise showed enhanced binding of Oct4 and Nanog at the
TERC locus (
Supplementary Fig. 9). However, we were unable to detect increased levels of nascent
TERC transcription by nuclear run-off assay in iPS cells versus fibroblasts (
Supplementary Fig. 10), suggesting that Oct4 and Nanog may affect transcriptional competence rather than transcriptional rate of the
TERC locus in pluripotent cells. Additional mechanisms are required to explain the increased steady-state levels of
TERC. To investigate post-transcriptional mechanisms of
TERC regulation, we determined
DKC1 levels, which correlate with
TERC levels in human cancer cells
19. In all normal and DC iPS lines tested, we found an increase in
DKC1 transcript levels and dyskerin protein relative to the fibroblasts ( and e). Moreover, we found that human ES cells, like iPS cells, maintain higher levels of
DKC1 (), that
DKC1 levels decreased with differentiation of iPS cells into embryoid bodies (
Supplementary Fig. 11a), and that
DKC1 knockdown caused a reduction in
TERC levels and compromised cellular viability (
Supplementary Figs. 11b,c). ChIP showed binding of Oct4 and Nanog to the
DKC1 promoter in pluripotent cells (), and infection of fibroblasts with retroviruses encoding the four reprogramming factors increased
DKC1 levels (
Supplementary Fig. 11d). These data establish that multiple telomerase components (
TERT,
TERC,
DKC1) are upregulated after reprogramming, thereby accounting for increased telomerase activity in the pluripotent state and explaining the restoration of telomere maintenance in DC iPS cells.
In an autosomal dominant DC patient carrying an 821 bp deletion in the 3' region of
TERC, prior studies have concluded that the haploinsufficient phenotype is explained by impaired post-transcriptional accumulation of
TERC RNA and reduced assembly of the truncated
TERC RNA into telomerase holoenzyme
20–22 (
Supplementary Fig. 12). Our ChIP data indicated Oct4 and Nanog binding in a region downstream of
TERC that overlaps the 821 bp deletion (). Moreover, we found that part of this region is predicted to have regulatory potential based on comparative genomic sequence alignment (
Supplementary Fig. 13a). We hypothesized that loss of this region might compromise transcriptional activity of the deleted allele. We employed two distinct allele-specific methods to analyze the chromatin configuration in
TERC+/− iPS cells, and in both cases found the mutant
TERC allele to be transcriptionally inactive (). First, allele-specific ChIP showed a striking abrogation of H3K4me3 marks and RNA polymerase II binding on the deleted allele ( and
Supplementary Figs. 13b and 13c). Second, allele-specific DNAse I hypersensitivity analysis showed pronounced nuclease accessibility at the
TERC promoter in normal cells () and on the normal allele in
TERC+/− cells, but complete loss of promoter hypersensitivity on the mutant
TERC allele (). Collectively, these results identify a
cis-element in the 3' region of the
TERC locus that appears essential for formation of a transcriptionally active chromatin structure, and suggest that mutations in this region can cause haploinsufficiency in autosomal dominant DC by diminishing
TERC transcription (
Supplementary Fig. 12).
By reprogramming somatic cells from patients with the human disease dyskeratosis congenita, we have discovered novel mechanisms of regulation of telomerase activity in the pluripotent state, thus illustrating the value of disease-specific iPS cells for basic and translational discovery. Moreover, we have shown that the RNA component of telomerase is upregulated in the pluripotent state to a degree sufficient to overcome limitations to telomere maintenance in X-linked and autosomal dominant DC. Drugs that activate the
TERC locus may favor telomere maintenance over premature attrition in stem cell compartments where
TERT is present but telomerase activity is limiting, such as hematopoietic stem cells
23–27, and thus might serve as therapeutic agents for bone marrow failure. Moreover, we speculate that in DC patients certain cell types such as germ cells and cancer cells, whose transcriptional programs share similarities with pluripotent cells, may also upregulate
TERC to permit germline propagation of mutations and malignant proliferation.